Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose-derived stem cells (AP-HM)
- Development stage
- Unknown
- Lead developer
- Centre Hospitalier Régional de Marseille
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intralesional
01
Overview
Autologous adipose-derived stem cell therapy is an investigational cell-based treatment being developed by the Centre Hospitalier Regional De Marseille (AP-HM) for the management of complex perianal fistulas in patients with Crohn's disease. The therapy involves harvesting mesenchymal stem cells (MSCs) from the patient's own adipose tissue via liposuction, followed by processing and local intralesional injection into the fistula tracts. These cells exert therapeutic effects through immunomodulation and the secretion of paracrine factors, including pro-angiogenic and anti-inflammatory cytokines. By suppressing local inflammation and promoting tissue regeneration, the therapy aims to achieve fistula closure in patients who are refractory to conventional medical and surgical interventions. Clinical evaluation is primarily conducted through the ADIPOCROHN trial series.
- Other names
- autologous adipose-derived cell therapyautologous adipose-derived mesenchymal stem cellsautologous AD-MSCsautologous ASCs
Beyond the preview
Go deeper on autologous adipose-derived stem cells (AP-HM).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose-derived stem cells (AP-HM).